Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 14 min ago
Peer-reviewedCC BY-NC-ND 4.0Molecular Psychiatry

Association between maintenance doses of mood stabilizers and antipsychotics and risk of readmission in first-episode bipolar disorder

  • Sunghyuk Kang1,2,3
  • Ji Hyun Baek4
  • Se Joo Kim1,2
  • Jee In Kang1,2
  • Hyeon Woo Yim5
  • Chung Mo Nam3
  • Sun Jae Jung3,6,7
7 affiliations
  1. 1Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea
  2. 2Institute of Behavioural Science in Medicine, Yonsei University College of Medicine, Seoul, Korea
  3. 3Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea
  4. 4Department of Psychiatry, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea
  5. 5Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
  6. 6Department of Public Health, Graduate School, Yonsei University, Seoul, Korea
  7. 7Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Korea
Read full textPDFDOICite

Abstract

Physicians aim to identify the lowest effective dose for maintenance pharmacotherapy in bipolar disorder, but evidence remains limited. We aimed to investigate the association between maintenance doses of mood stabilizers and antipsychotics and relapse risk in patients with first-episode bipolar disorder. Using the Korean National Health Insurance Database, we identified patients aged 19–60 years with a first admission for bipolar disorder between 2002 and 2022. After discharge from the first admission (acute phase), maintenance doses of mood stabilizers and antipsychotics were assessed as absolute doses (defined daily doses [DDDs]/day) and relative doses (percentages of the acute-phase dose) during follow-up. The outcome was readmission for mood disorders. Hazard ratios (HRs) and 95% confidence intervals (CIs) for readmission according to time-varying maintenance doses were estimated using time-dependent Cox regression. A negative dose–response relationship between mood stabilizer dose and readmission was observed below 0.4 DDDs/day (absolute) and 80% (relative) in both the continuous and categorical analyses. For antipsychotics, a progressively higher risk of readmission was observed below 0.5 DDDs/day and 50%, with a near plateau above these levels. Joint dose-category analyses suggested that increased readmission risk associated with low-dose mood stabilizers or antipsychotics was attenuated when the other class was used above the observed dose threshold. In time-stratified analyses, these associations were significant after three years of follow-up. This study found that maintenance doses of mood stabilizers and antipsychotics below specific levels were associated with increased readmission risk in first-episode bipolar disorder, which may help inform clinically cautious dose reduction strategies.

Related

  1. Evaluating the Real-World Safety of Atypical Antipsychotics in Paediatric Autism Spectrum Disorder: Lessons from Saudi Arabia's Pharmacovigilance System.
    M. Aljead, M. Almeziny, E. Alghamdi +2
    medRxivPreprintCC BYFull textPsychiatry & mental healthmedRxiv
  2. Real-World Status of Augmentation Therapy With Atypical Antipsychotics in Major Depressive Disorder: A Claims Database Study.
    Hikaru Hori, Yoshiyuki Shibasaki, Yuki Shiomi +6
    Neuropsychopharmacology reportsPeer-reviewedCC BY-NCFull textPharmacology & toxicologyEurope PMCPMC
  3. Pathways to medication adherence: a configurational analysis of psychiatric symptoms and medication attitude in patients with schizophrenia spectrum disorder receiving long-acting injectable antipsychotics.
    Linghui Zhang, Yubin Chen, Hong Yu +6
    BMC psychiatryPeer-reviewedCC BY-NC-NDFull textPsychiatry & mental healthEurope PMCDOAJPMC
  4. Association between metabolic overweight/obesity phenotypes and readmission risk in patients with Immune Thrombocytopenia (ITP): a national retrospective study.
    Fuxin Xu, Tongxin Wang, Lingquan Meng +4
    Annals of hematologyPeer-reviewedCC BYFull textGeneral medicineEurope PMCDOAJ
  5. Association Between Eosinophils and Readmission in Patients with Eosinophil-Fluctuating AECOPD: A Multi-Threshold PWP-GT Analysis
    Yaya Gong, Peng Zhang, Hongyan Sun +1
    International Journal of Chronic Obstructive Pulmonary DiseasePeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC

Cite

BibTeXRIS
BibTeX
@article{kang2026association,
  title = {{Association between maintenance doses of mood stabilizers and antipsychotics and risk of readmission in first-episode bipolar disorder}},
  author = {Sunghyuk Kang and Ji Hyun Baek and Se Joo Kim and Jee In Kang and Hyeon Woo Yim and Chung Mo Nam and Sun Jae Jung},
  journal = {Molecular Psychiatry},
  year = {2026},
  month = jul,
  doi = {10.1038/s41380-026-03782-2},
  url = {https://doi.org/10.1038/s41380-026-03782-2},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Association between maintenance doses of mood stabilizers and antipsychotics and risk of readmission in first-episode bipolar disorder
AU  - Sunghyuk Kang
AU  - Ji Hyun Baek
AU  - Se Joo Kim
AU  - Jee In Kang
AU  - Hyeon Woo Yim
AU  - Chung Mo Nam
AU  - Sun Jae Jung
PY  - 2026
DA  - 2026/07/31
JO  - Molecular Psychiatry
DO  - 10.1038/s41380-026-03782-2
UR  - https://doi.org/10.1038/s41380-026-03782-2
AB  - Physicians aim to identify the lowest effective dose for maintenance pharmacotherapy in bipolar disorder, but evidence remains limited. We aimed to investigate the association between maintenance doses of mood stabilizers and antipsychotics and relapse risk in patients with first-episode bipolar disorder. Using the Korean National Health Insurance Database, we identified patients aged 19–60 years with a first admission for bipolar disorder between 2002 and 2022. After discharge from the first admission (acute phase), maintenance doses of mood stabilizers and antipsychotics were assessed as absolute doses (defined daily doses [DDDs]/day) and relative doses (percentages of the acute-phase dose) during follow-up. The outcome was readmission for mood disorders. Hazard ratios (HRs) and 95% confidence intervals (CIs) for readmission according to time-varying maintenance doses were estimated using time-dependent Cox regression. A negative dose–response relationship between mood stabilizer dose and readmission was observed below 0.4 DDDs/day (absolute) and 80% (relative) in both the continuous and categorical analyses. For antipsychotics, a progressively higher risk of readmission was observed below 0.5 DDDs/day and 50%, with a near plateau above these levels. Joint dose-category analyses suggested that increased readmission risk associated with low-dose mood stabilizers or antipsychotics was attenuated when the other class was used above the observed dose threshold. In time-stratified analyses, these associations were significant after three years of follow-up. This study found that maintenance doses of mood stabilizers and antipsychotics below specific levels were associated with increased readmission risk in first-episode bipolar disorder, which may help inform clinically cautious dose reduction strategies.
SN  - 1359-4184
SN  - 1476-5578
ER  -